SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)
$ALLO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/16/2026 | Underweight → Neutral | Analyst | |
| 4/10/2026 | $6.00 | Buy | Jefferies |
| 1/9/2026 | $5.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 10/10/2025 | Neutral → Underweight | Analyst | |
| 5/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 3/14/2025 | $5.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 8/8/2024 | $13.00 → $11.00 | Outperform | Oppenheimer |
| 5/31/2024 | $11.00 | Overweight | Piper Sandler |
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
DEFA14A - Allogene Therapeutics, Inc. (0001737287) (Filer)
8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)
DEFA14A - Allogene Therapeutics, Inc. (0001737287) (Filer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
Analyst upgraded Allogene from Underweight to Neutral
Jefferies resumed coverage of Allogene with a rating of Buy and set a new price target of $6.00
Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00
David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of DirectorsZachary Roberts, M.D., Ph.D., EVP, Research & Development and Chief Medical Officer, Appointed President and Chief Executive Officer and to the Board of Directors Effective July 1, 2026 SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Dr. David Chang, M.D., Ph.D., will transition from his role as Pr
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences. TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Tuesday, May 2612:30PM PT/3:30PM ET Jefferies Global Healthcare Conference, New York Wednesday, June 3 5:10AM PT/8:10AM ET H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceTuesday, June 9 Any available webcasts will be posted to the Company's website at www.allogene.com under the Inve
Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel's (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL) 58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD) Clearance Compared with 16.7% (2/12) in the Observation ArmAt Day 45, ctDNA Levels Decreased by a Median of 97.7% from Baseline in the Cema-Cel Arm Versus a Median Increase of 26.6% in the Observation ArmFavorable Safety Profile with No CRS, ICANS, GvHD, or Treatment-Related Serious Adverse Events or Hospitalizations, Enabling Majority Outpatient ManagementApproximately One-Third of Screening Activ
David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of DirectorsZachary Roberts, M.D., Ph.D., EVP, Research & Development and Chief Medical Officer, Appointed President and Chief Executive Officer and to the Board of Directors Effective July 1, 2026 SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Dr. David Chang, M.D., Ph.D., will transition from his role as Pr
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. "Geoff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities," said David Chang, M.D., Ph.D.
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report the first quarter 2026 financial results and provide a business update on May 13, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2 p.m. PT/5 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at www.allogene.com und
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (MRD) following 1L therapy. These patients are then randomized either to cema-cel, an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene, or observation. The interim analysis showed that 58.3% of MRD-positive pat
41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7% Median Decrease in Plasma ctDNA at Day 45 Compared to a 26.6% Median Increase in the Observation ArmCema-Cel Treatment Well-Tolerated with Most Patients Managed Outpatient No Cases of CRS, ICANS, GvHD, or Treatment-Related Serious Adverse EventsNo Hospitalizations for Treatment-Related Adverse Events Community Cancer Centers, Including Sites New to CAR T Therapy, Accounted for Approximately 33% of Screening Activity and Cema-Cel Infusions Enrollment Expected to Complete by Year-En
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)